within Pharmacolibrary.Drugs.ATC.A;

model A05BA10
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.3,
    Cl             = 0.00016666666666666666,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A05BA10</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Phospholipids are amphipathic molecules used therapeutically to support hepatic function, primarily as hepatoprotective agents in various liver diseases. Formulations like essential phospholipids are indicated for liver disorders such as hepatitis, fatty liver, and liver toxicity. While widely used in some countries (notably Eastern Europe and Asia), these agents are not universally approved and are considered nutraceuticals or adjunct therapies in others.</p><h4>Pharmacokinetics</h4><p>No primary pharmacokinetic data exist in indexed literature for therapeutic phospholipids (essential phospholipids) in healthy adults or patients with liver disease. Parameters are estimated based on physicochemical characteristics and analogous lipid formulations.</p><h4>References</h4><ol><li><p>Cholewski, M, et al., &amp; Tomczyk, M (2018). A Comprehensive Review of Chemistry, Sources and Bioavailability of Omega-3 Fatty Acids. <i>Nutrients</i> 10(11) –. DOI:<a href=&quot;https://doi.org/10.3390/nu10111662&quot;>10.3390/nu10111662</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30400360/&quot;>https://pubmed.ncbi.nlm.nih.gov/30400360</a></p></li><li><p>Carlin, AF, et al., &amp; Hostetler, KY (2024). Oral pharmacokinetics and efficacy of oral phospholipid remdesivir nucleoside prodrugs against SARS-CoV-2 in mice. <i>Antimicrobial agents and chemotherapy</i> 68(10) e0103924–None. DOI:<a href=&quot;https://doi.org/10.1128/aac.01039-24&quot;>10.1128/aac.01039-24</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/39240093/&quot;>https://pubmed.ncbi.nlm.nih.gov/39240093</a></p></li><li><p>Fricker, G, et al., &amp; Müller-Goymann, C (2010). Phospholipids and lipid-based formulations in oral drug delivery. <i>Pharmaceutical research</i> 27(8) 1469–1486. DOI:<a href=&quot;https://doi.org/10.1007/s11095-010-0130-x&quot;>10.1007/s11095-010-0130-x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20411409/&quot;>https://pubmed.ncbi.nlm.nih.gov/20411409</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A05BA10;
